



September 7, 2010

MannKind to Present at Upcoming Conferences

VALENCIA, Calif., Sep 07, 2010 (BUSINESS WIRE) -- **MannKind Corporation (Nasdaq: MNKD)**, focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at upcoming conferences.

- Morgan Stanley Global Healthcare Conference on September 13, 2010 at 1:35 PM EDT at the Grand Hyatt in New York, NY
- Baird Healthcare Conference on September 14, 2010 at 1:45 PM EDT at the St. Regis Hotel in New York, NY
- Rodman & Renshaw Annual Global Investment Conference on September 14, 2010 at 2:00 PM EDT at the New York Palace Hotel in New York, NY
- Imperial Capital Annual Global Opportunities Conference on September 15, 2010 at 8:35 AM EDT at the Grand Hyatt in New York, NY
- UBS Global Life Sciences Conference on September 21, 2010 at 3:00 PM EDT at the Grand Hyatt in New York, NY
- JMP Securities Healthcare Conference on September 28, 2010 at 9:30 AM EDT at the New York Palace Hotel in New York, NY

Interested parties can access a link to the live webcast of the presentations from the News & Media section of the Company's website at <http://www.mannkindcorp.com>. Replays of the presentations will be available for 14 days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its diabetes pipeline includes AFREZZA™ and MKC253. MKC253 is currently in phase 1 clinical trials. In March 2009, MannKind submitted a NDA to the FDA requesting approval of AFREZZA for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. In March 2010, MannKind received a Complete Response letter to this NDA from the FDA, requesting additional information. In July 2010, the FDA accepted MannKind's reply to the Complete Response letter and set a PDUFA action date of December 29, 2010. Other products in MannKind's pipeline include the cancer immunotherapy products MKC1106-PP and MKC1106-MT, which are currently in phase 1 clinical trials. MannKind maintains a website at <http://www.mannkindcorp.com> to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

SOURCE: MannKind Corporation

MannKind Corporation
Matthew J. Pfeffer
Corporate Vice President and
Chief Financial Officer
661-775-5300
mpfeffer@mannkindcorp.com